The investigators had several important findings.
France. Both authors have reported that they have no relationships relevant to the contents of this paper to disclose. One of the initial concerns that the study investigators had regarding the stent was the fear that rapid drug elution would affect stent efficacy, as shown with earlier polymer-free stents such as the Yukon stent, which was associated with an instent LLL of 0.48 mm (i.e., higher than a PES comparator) (12, 13) . Importantly, this fear was unfounded. Costa et al. (5) suggest that Biolimus A9 may have optimal pharmacokinetics due to its high lipophilic nature, allowing for a fast but extended treatment effect while counteracting the boost effect (8) .
As far as safety of the stent, although no cases of ST occurred, the study was not powered for such rare has the same safety and efficacy compared with a second-generation DES in a nonselected population remains to be proven. This is again an exciting time for coronary intervention, as the quest for the ideal personalized coronary stent seems to become a reality. 
